Security Reports > Global Blood Therapeutics

Global Blood Therapeutics
Data Breaches, Cyber Attacks and Security Report

https://gbt.com  ᛫  Biotech & Pharmaceuticals
Last updated August 7, 2020

Global Blood Therapeutics Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Global Blood Therapeutics is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Global Blood Therapeutics

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.


Data Breaches and Security News


Security Report for Global Blood Therapeutics

Want a security rating for your organization?

This report shows a preliminary security rating for Global Blood Therapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Global Blood Therapeutics's security performance with other companies